Who
Jonathan C. Fox
Director
Company insider
Files Form 4 as: Director, Edgewise Therapeutics; Officer, Eidos Therapeutics; Chief Medical Officer, MyoKardia.
In numbers
- Trades disclosed
- 65
- Buys
- 3
- Sells
- 26
- Bought
- $330K
- Sold
- $7.3M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 3 Nov 2015
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code A | —308 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code A | —319 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code A | —319 at $0.00 | filing |
| 5 Jun 2026filed 16 Jun 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,377 at $0.00 | filing |
| 5 Jun 2026filed 16 Jun 2026 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,377 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code A | —339 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code A | —339 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code A | —473 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code A | —473 at $0.00 | filing |
| 11 Nov 2025filed 13 Nov 2025 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Bought | $199K10,700 at $18.64 | filing |
| 1 Oct 2025filed 2 Oct 2025 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code A | —728 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code A | —858 at $0.00 | filing |
| 16 Jun 2025filed 18 Jun 2025 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Code A | —559 at $0.00 | filing |
| 10 Jun 2024filed 12 Jun 2024 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,594 at $0.00 | filing |
| 26 Dec 2023filed 28 Dec 2023 | EWTX Edgewise TherapeuticsBiotechnology | SEC FORM 4 Bought | $101K10,857 at $9.30 | filing |
| 12 Jun 2023filed 14 Jun 2023 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,123 at $0.00 | filing |
| 3 Mar 2023filed 7 Mar 2023 | EWTX Edgewise Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,731 at $0.00 | filing |
| 26 Jan 2021filed 28 Jan 2021 | Eidos Therapeutics | SEC FORM 4 Code U | —380,467 | filing |
| 26 Jan 2021filed 28 Jan 2021 | Eidos Therapeuticsoption or derivative | SEC FORM 4 Code D | —70,000 | filing |
News
Edgewise Therapeutics Doses First Patient In Phase 2 HFpEF Trial; Stock DownEWTX · rttnews.com · 8 Oct 2026
0 headlines in the last 90 days name Jonathan C. Fox; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.